You are here

Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease

Last updated on May 12, 2018

FOR MORE INFORMATION
Study Location
Sacramento, California, 95819 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Arrhythmia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with or without ICDs (implantable cardioverter defibrillators)

- Patients undergoing an electrophysiology study for evaluation of ventricular rhythm

- Patients with a history of heart disease

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with uncontrolled blood pressure

- Patients with certain cardiac risk factors

- Patients with significant kidney or liver problems

NCT00137332
Pfizer
Terminated
Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Arrhythmia
NCT00137332
All Genders
18+
Years
Multiple Sites
Arrhythmia
NCT00137293
All Genders
18+
Years
Multiple Sites
Arrhythmias
NCT00124891
All Genders
18+
Years
Multiple Sites
Arrhythmia
NCT00457340
All Genders
18+
Years
Multiple Sites
Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease
A Study of the Effects GAP-486 on Ventricular Tachyarrhythmia Induction
The purpose of this study is to learn the effects of a test drug on heart rhythms, which may become life-threatening if left untreated, and to provide data to see if the drug is well tolerated and safe.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Arrhythmia
  • Drug: GAP-486 (ZP-123)
  • Drug: 0.9% Sodium Chloride, USP
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
90
October 2006
Not Provided

Inclusion Criteria:

  • Patients with or without ICDs (implantable cardioverter defibrillators)
  • Patients undergoing an electrophysiology study for evaluation of ventricular rhythm
  • Patients with a history of heart disease

Exclusion Criteria:

  • Patients with uncontrolled blood pressure
  • Patients with certain cardiac risk factors
  • Patients with significant kidney or liver problems
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   United States
 
 
NCT00137332
3163K1-202
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
December 2007

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now